Monte Rosa Therapeutics, Inc.(GLUE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,494 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in GLUE
Events flagged as statistical outliers against GLUE's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
GLUE quality score jumped 13 points (18→31) on a new filing
View source filing →
GLUE Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Monte Rosa Therapeutics, Inc. (GLUE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GLUE at 30.3/100 on a 32-signal composite quality model, placing it at rank #2,494 of 2,961 stocks — the bottom half of the AI-ranked universe. GLUE scores in the top quartile across revenue growth (97.8). Areas of concern include profitability (3.1) and revenue scale (4.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Monte Rosa Therapeutics, Inc. reports quarterly revenue of $9.0M, net income of $-43.4M, free cash flow of $-48.8M. Top institutional holders of GLUE by reported 13-F value include PRICE T ROWE ASSOCIATES, NEA Management Company, BlackRock, based on the most recent SEC filings. GLUE trades on the Nasdaq exchange and files with the SEC under CIK 1826457. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Monte Rosa Therapeutics, Inc. directly from SEC EDGAR. Monte Rosa Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 12 and 56 since 2026, currently 30.3 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$9.0M
Net Income
Q2 2026
$-43.4M
Free Cash Flow
Q2 2026
$-48.8M
ROIC
Q2 2026
-40.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+63.5% YoYNet Income
+46.9% YoYOperating Income
+33.2% YoYTotal Assets
+2.3% YoYOp. Cash Flow
-154.3% YoYFree Cash Flow
-172.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $123.7M +63.5% | $75.6M | $0.00 | — | — | — |
| Net Income | $-38.6M +46.9% | $-72.7M +46.3% | $-135.4M -24.7% | $-108.5M -46.7% | $-74.0M -106.1% | $-35.9M |
| Operating Income | $-54.2M +33.2% | $-81.1M +43.4% | $-143.3M -27.5% | $-112.4M -54.2% | $-72.9M -160.2% | $-28.0M |
| Total Assets | $448.7M +2.3% | $438.7M +44.4% | $303.8M -11.3% | $342.4M -6.5% | $366.3M +641.9% | $49.4M |
| Operating Cash Flow | $-22.8M -154.3% | $42.0M +195.9% | $-43.8M +52.6% | $-92.5M -55.8% | $-59.4M -157.5% | $-23.1M |
| Free Cash Flow | $-27.5M -172.3% | $38.0M +160.5% | $-62.8M +40.4% | $-105.4M -52.5% | $-69.1M -161.3% | $-26.4M |
Get alerted when GLUE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Monte Rosa Therapeutics, Inc. including:
Top Institutional Holders of GLUE
PRICE T ROWE ASSOCIATES INC /MD/
$214.4M8,861,171 shNEA Management Company, LLC
$186.2M7,692,298 shBlackRock, Inc.
$165.6M6,843,087 shTCG Crossover Management, LLC
$111.9M4,622,151 shVestal Point Capital, LP
$111.3M4,600,000 shBVF INC/IL
$108.0M4,460,886 shBAKER BROS. ADVISORS LP
$105.2M4,345,736 shSTATE STREET CORP
$90.3M3,731,416 shSUVRETTA CAPITAL MANAGEMENT, LLC
$85.9M3,549,539 shVANGUARD CAPITAL MANAGEMENT LLC
$82.6M3,412,927 sh
| Fund | Value | Shares |
|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | $214.4M | 8,861,171 |
| NEA Management Company, LLC | $186.2M | 7,692,298 |
| BlackRock, Inc. | $165.6M | 6,843,087 |
| TCG Crossover Management, LLC | $111.9M | 4,622,151 |
| Vestal Point Capital, LP | $111.3M | 4,600,000 |
| BVF INC/IL | $108.0M | 4,460,886 |
| BAKER BROS. ADVISORS LP | $105.2M | 4,345,736 |
| STATE STREET CORP | $90.3M | 3,731,416 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $85.9M | 3,549,539 |
| VANGUARD CAPITAL MANAGEMENT LLC | $82.6M | 3,412,927 |
Companies Similar to GLUE
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Aclaris Therapeutics, Inc.
Silence Therapeutics plc
Voyager Therapeutics, Inc.
Zymeworks Inc.
Relay Therapeutics, Inc.
uniQure N.V.
ALUMIS INC.
Entrada Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put GLUE on your watchlist
Track score changes the day Monte Rosa Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GLUE a good stock to buy?
13F Pro's AI-powered analysis of Monte Rosa Therapeutics, Inc. (GLUE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GLUE are available on the GLUE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GLUE is classified as a small company.
Which hedge funds own GLUE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GLUE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Monte Rosa Therapeutics, Inc.'s investment landscape.